Sakar Healthcare Limited

SAKAR

INE732S01012

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:53 2024-05-17 am EDT			5-day change	1st Jan Change
345.6 ^INR	+0.17%		+1.35%	-13.61%

Mar. 06	Sakar Healthcare Ltd Receives EU GMP Approval Dated 5th March 2024With A Validity of Three Years from Audited Date	CI
Feb. 10	Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Sakar Healthcare Limited Announces Earnings Results for the First Quarter Ended June 30, 2020

August 17, 2020 at 07:34 am EDT

Sakar Healthcare Limited announced earnings results for the first quarter ended June 30, 2020. For the quarter, the company announced total revenue was INR 203.808 million compared to INR 167.236 million a year ago. Net income was INR 25.879 million compared to INR 16.123 million a year ago. Basic earnings per share was INR 1.72 compared to INR 1.08 a year ago.

Latest news about Sakar Healthcare Limited

Sakar Healthcare Ltd Receives EU GMP Approval Dated 5th March 2024With A Validity of Three Years from Audited Date	Mar. 06	CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 10	CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 06	CI
Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Sakar Healthcare Limited announced that it expects to receive INR 599.999123 million in funding from Tata Investment Corporation Limited	23-08-02	CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-26	CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-10-22	CI
Indian shares seen opening lower; U.S. jobs data in focus	22-10-06	RE
Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-06	CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-20	CI
Sakar Healthcare Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-20	CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-08	CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-10-29	CI
Sakar Healthcare's Fully-Integrated Anti-Cancer Formulation Unit, Now Starting with Research Laboratories	21-09-22	CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-05-31	CI
Sakar Healthcare Limited announced that it has received INR 148.5 million in funding from HBM Partners Ltd.	21-05-13	CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-05	CI
Sakar Healthcare Limited Announces Executive Changes	20-10-28	CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-10-28	CI
Sakar Healthcare Limited Receives European Union GMP Approval for the Small Volume Parenteral Unit Manufacturing Liquid Injections & Lyophilized Injections	20-10-06	CI
Sakar Healthcare Limited Appoints Hemendrakumar Chamanlal Shah as an Independent Director	20-09-27	CI
Sakar Healthcare Limited Announces Resignation of Hardik P. Mehta as Independent Director	20-09-27	CI
Sakar Healthcare Limited Announces Earnings Results for the First Quarter Ended June 30, 2020	20-08-17	CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	20-06-25	CI

Chart Sakar Healthcare Limited

Duration

Period

More charts

Company Profile

Sakar Healthcare Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company is engaged in providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules, vials and lyophilized injections, oral solid dosages, and research and development of these products. The Companyâs products include Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid and Lyophilised Injections (In Vials). The Company operates as a contract development and manufacturing organization (CDMO). The Company has approximately 321 product registrations in various countries. The manufacturing unit has been accredited by regulatory authorities of 14 countries, which includes Uganda, Kenya, Yemen, Ethiopia, Congo, Zimbabwe, Nigeria, Malawi, Philippines, Peru, Vietnam, Cote DâIvoire.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SAKAR HEALTHCARE LIMITED	-13.61%	78.68M
KYOWA KIRIN CO. LTD.	+10.23%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.21B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+53.60%	4.83B
YUHAN CORPORATION	+7.56%	4.09B
BETTA PHARMACEUTICALS CO., LTD.	-21.42%	2.35B
INDIVIOR PLC	+14.51%	2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+25.03%	2.27B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-30.36%	2.19B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals